Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.
Location: United States, Massachusetts, Cambridge
Member count: 11-50
Total raised: $100M
Founded date: 2021
Investors 2
| Date | Name | Website |
| - | Access Bio... | accessbio-... |
| 16.10.2022 | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 17.10.2022 | Series A | $100M | - | finsmes.co... |
Mentions in press and media 2
| Date | Title | Description | Category | Author | Source |
| 17.10.2022 | Matchpoint... | Matchpoint Therapeutics, a Cam... | USA | - | finsmes.co... |
| - | Matchpoint... | “Matchpoint aims to discover a... | - | - | fastfounde... |